A Noninterventional, Cross-Sectional Study to Assess Patient Prostate Cancer Treatment Preferences and Experiences in...

Area of Science:

• Oncology
• Endocrinology
• Patient-Reported Outcomes

Background:

• Gonadotropin-releasing hormone (GnRH) agonist injection frequency impacts prostate cancer patient satisfaction, adherence, and healthcare use, despite not affecting treatment efficacy.
• Real-world patient experiences with varying GnRH treatment frequencies remain under-documented.

Purpose of the Study:

• To investigate European prostate cancer patient preferences and satisfaction with different Gonadotropin-releasing hormone (GnRH) agonist injection frequencies.
• To understand factors influencing patient choice and satisfaction regarding injection schedules.

Main Methods:

• A cross-sectional, noninterventional survey of 414 adult patients with locally advanced or metastatic prostate cancer across five European countries.
• Data collected via electronic survey (October-December 2023) on preferences, satisfaction, healthcare resource utilization, and decision-making.

Main Results:

• 53.9% of patients preferred 6-month injections, compared to 27.3% preferring 3-month intervals, with higher satisfaction reported for 6-month frequency (77.0% vs. 62.7%).
• Convenience and routine were key drivers for 6-month preference; fear of injections was cited by 7.2%.
• Most patients required transport and time off work for injections, and preferred accompaniment.

Conclusions:

• Less-frequent GnRH agonist injections (e.g., every 6 months) appear more convenient and preferred by many prostate cancer patients, leading to higher satisfaction.
• Findings support patient-centric care by informing treatment decisions and optimizing management strategies for prostate cancer.